The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.
Study Type
OBSERVATIONAL
Enrollment
120
Research Site
Berlin, Germany
Research Site
Essen, Germany
Research Site
Heidelberg, Germany
Research Site
Hemer, Germany
Research Site
Karlsruhe, Germany
Research Site
Löwenstein, Germany
Research Site
München, Germany
Research Site
Trier, Germany
To obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC stage IIb/IV who are in transition from 1st line to 2nd line treatment
Time frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy
current medical practice treatment objectives and modalities side effects
Time frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy
socioeconomic status and demographics patients' perception of their health status and treatment patient values and patient preferences
Time frame: once only, 4-6 weeks after switch from 1st to 2nd line chemotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.